Scailyte, a Switzerland-based med-tech company, announced that it has raised CHF6M in Series A funding. This latest investment round was led by a Swiss family office, Mirabaud bank, and existing investors.
Founded in 2017, and based in Basel, Switzerland, Scailyte is a medical technology company developing artificial intelligence technology to enable precision medicine and early detection of complex diseases. The Swiss startup has created a data-driven biomarker discovery platform that leverages unique expertise in single-cell technologies and artificial intelligence technology.
The company has already raised $13.8 million in total funding, according to startup profiler Crunchbase. The newly-raised capital will be used to accelerate growth, and expand operations and business reach.
Scailyte currently has 7 active investors, including Mirabaud and Swisscom Ventures. The company competes with the likes of Israeli-based biotech firm CytoReason, US healthcare Imagen Technologies, and Incepto Medical, a Paris-based provider of medical imaging solutions.